Despite the very modest impact of GDF15 and FGF21 ‘loss-of-function’ on body weight, they remain of considerable interest as pharmacological ‘gain-of-function’ targets in relation to their impact on body weight and on hepatic steatosis. This evidence concerns the gene GDF15 and fatty liver disease.